(-)-Epigallocatechin Gallate

製品コードS2250 別名:EGCG

(-)-Epigallocatechin Gallate化学構造

分子量(MW):458.37

(-)-Epigallocatechin Gallate(EGCG) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity.

サイズ 価格(税別)  
JPY 26560.00
JPY 8300.00
JPY 11620.00

カスタマーフィードバック(4)

  • (a) Huh7 cells were incubated with HCVcc of JFH-1 for 2 h before overlaying with 1% agarose dissolved in culture medium or with AR3A anti-E2 neutralizing antibodies, in the presence of 20 μg/ml SZA. EGCG (50 μM) was introduced as a positive control. At 48 h post-infection, infected cells were quantified by IF. Nuclei were stained with DAPI. (b) Numbers of cells per positive colony were determined in 15 foci.

    Sci Rep, 2016, 6:27268.. (-)-Epigallocatechin Gallate purchased from Selleck.

    EGCG treatment increases cTnI protein levels in ageing hearts. (A) Western blotting analysis using cTnI and cTnT antibodies. b-Actin was used as protein loading control. (B) A summary of Western blotting results of cTnI. Values are expressed as mean S.D. from four separate experiments. Statistical significance was determined by ANOVA followed by least significant difference (LSD) tests. *P < 0.05 as compared with the 18M + EGCG and 3M groups. EGCG: epigallocatechin-3-gallate

    J Cell Mol Med, 2017, 21(10):2481-2490. (-)-Epigallocatechin Gallate purchased from Selleck.

  • PLoS One 2013 8(8), e69519. (-)-Epigallocatechin Gallate purchased from Selleck.

    PLoS One 2013 8(8), e69519. (-)-Epigallocatechin Gallate purchased from Selleck.

製品安全説明書

Telomerase阻害剤の選択性比較

生物活性

製品説明 (-)-Epigallocatechin Gallate(EGCG) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity.
体外試験

(-)-Epigallocatechin gallate functions as a powerful antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic and antitumor agent and as a modulator of tumor cell response to chemotherapy. (-)-Epigallocatechin gallate shows multiple anticancer effects, such as anti-proliferation, anti-angiogenesis, transformation prevention of various cancer cells, cancer cell cycle arrest and inhibition of tumor metastasis. (-)-Epigallocatechin gallate exerts multi-anticancer effects through regulating several cancer-related cell signal pathways (regulated the function or the expression of key signal proteins, such as nuclear factor-κB, MAPKs and activator protein-1, EGFR, IGF, COX-2 signaling pathway, and so on.), effecting methylation of cancer genes and combination of ligand with membrane receptors. [1] (-)-Epigallocatechin gallate also shows an immunomodulating effects. Several types of immune cells in both the innate and adaptive immune systems are known to be affected in varying degrees by (-)-Epigallocatechin gallate. Among them, the dramatic effect on T cell functions has been repeatedly demonstrated, including T cell activation, proliferation, differentiation, and production of cytokines. Studies using animal models of autoimmune diseases have reported disease improvement in animals treated with green tea/EGCG. [2] (-)-Epigallocatechin gallate displays anti-infective properties. Antiviral activities of (-)-Epigallocatechin gallate with different modes of action have been demonstrated on diverse families of viruses, such as Retroviridae, Orthomyxoviridae and Flaviviridae and include important human pathogens like human immunodeficiency virus, influenza A virus and the hepatitis C virus. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SH-SY5Y cells NVz4WJh{TnWwY4Tpc44h[XO|YYm= MkTPUoV2em:ycn;0[YN1cW:wIHHnZYlve3RiYnX0ZU1idXmub3nkJJBmeHSrZHWgNU01Oi2rbnT1Z4VlKHSxeHnjbZR6KGmwIHj1cYFvKFOKLWPZOXkh[2WubIOgZZN{\XO|ZXSgZZMhdGGldHH0[UBl\Wi7ZILv[4Vv[XOnIILlcIVie2VuIFXDOVA:OC5yM{m4O{DPxE1? NVLmT2xsOTlzM{i4OVk>
human MDA435/LCC6MDR cells NUKyZoFDTnWwY4Tpc44h[XO|YYm= NFX2WJgyOCEQvF2= NHrVUYY2KGSjeYO= MVzNc4R2dGG2aX;uJI9nKFBvZ4CgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCqdX3hckBOTEF2M{WvUGNEPk2GUjDj[YxteyCjc4Pld5Nm\CCjczDy[ZZmenOrYnzlJI9nKHCjY3zpeIF5\WxicnXzbZN1[W6lZTDt[YF{fXKnZDDhd{BKSzVyIH\vdkBx[WOuaYThfIVtKGG2IEGwJJVOKGGodHXyJFUh\GG7czDifUBE\WyuVHn0[ZIhQTZiQYH1[Y92eyCjc4PhfUwhUUN3ME2wMlEzOjZizszN MlT1NlU6QDVzOUW=
Sf9 cells NVKxZWh7TnWwY4Tpc44h[XO|YYm= NXTUeXNtUW6qaXLpeIlwdiCxZjDIbZM3NXSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBFVk2WMTDlfJBz\XO|ZXSgbY4hcW6|ZXP0JHNnQSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSG5CKG2ndHj5cJRz[W6|ZnXyZZNmKGGldHn2bZR6KHW|aX7nJFUoNWKrb4Tpcplt[XSnZDC0OU1jeCC3bn3leIh6dGG2ZXSgc5IhcGWvaX3leIh6dGG2ZXSgc4xq\2:wdXPs[Y91cWSnIIP1ZpN1emG2ZYOgZY5lKFt|SG2tRYRwVWW2IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3ME2wMlUh|ryP NFzRTFczPTRyNkm0OC=>
human U937 cells MXfGeY5kfGmxbjDhd5NigQ>? M1LScGlvcGmkaYTpc44hd2ZidHXsc41memG|ZTDpckBpfW2jbjDVPVM4KGOnbHzzMEBKSzVyPUGg{txO MnL6NlI1OTN6NEW=
human HeLa cells MlvQSpVv[3Srb36gZZN{[Xl? NWWyPZdvUW6qaXLpeIlwdiCxZjD0[YxwdWW{YYPlJIlvKGi3bXHuJGhmVGFiY3XscJMhfXOrbnegOUcuSUGWIFPDS{BVS0diQVfDJGFISSCJVGStN{ch[XNic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhOTVibXnud{BxemmxcjD0c{BmgHSnboPpc44hemWjY4Tpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCkeTDzdIlvNXSnbH;t[ZJq[yC{ZYDlZZQh[W2ybHnmbYNifGmxbjDwdo91d2OxbDygTWM2OD1zLkC4JO69VQ>? NEXT[nkzOjRzM{i0OS=>
CHO cells M1rEXmN6fG:2b4jpZ:Kh[XO|YYm= MmPaOFghcA>? M4j2bWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEOKTzDj[YxteyCneIDy[ZN{cW6pIF;BWHAySjNiaHHwcI91gXCnIEGgZYZ1\XJiNEigbJJ{KGK7IH\seY9z\XOlZX7j[UBj[XOnZDDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyPUOuNkDPxE1? MUWyN|MzPzh5Nx?=
MDCK cells MWLGeY5kfGmxbjDhd5NigQ>? M{XXR|Qh\GG7cx?= NFnJUnFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBqdm[udXXufoEhSSC4aYL1d{ApSS:|d3nu[U9QUC93MUG0OFUwOjByNzjINW4yMSliT3i3JIlv\mWldHXkJIlvKE2GQ1ugZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkA1KGSjeYOgZpkheXWjboTpeIF1cX[nIGLUMXBEWixiRVS1NF05NjNizszN MkPJNlIyOTV3OUG=
human HL60 cells M{DyNnBzd2yrZnXyZZRqd25iYYPzZZk> Mn7qN{Bl[Xm| M{\WbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUC9PU41KM7:TR?= MnftNVg3QTNyMkC=
HSC-T6 cells  MoHWSpVv[3Srb36gZZN{[Xl? MXm0PEBp MXXBcpRq\mmkcn;0bYMh[WO2aY\peJkh[WejaX7zeEBz[XRiSGPDMXQ3KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gdJJwdGmoZYLheIlwdiCjZoTldkA1QCCqcoOgZpkhSnKmVTDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUmuPUDPxE1? MVeyNVUxPDh2OB?=
mouse 3T3-L1 cells MWnGeY5kfGmxbjDhd5NigQ>? MmTZTY5pcWKrdHnvckBw\iCJNmDEMY1m\GmjdHXkJG5CTFCKIIDyc4R2[3Srb36gbY4hdW:3c3WgN3Q{NUxzIHPlcIx{NCCLQ{WwQVI2KM7:TR?= NV\QUWQ6OTh|MUOzNFg>
mouse RAW264.7 cells NEHuOYNHfW6ldHnvckBie3OjeR?= MY[1JIRigXN? M4jpeWlvcGmkaYTpc44hd2ZiUlHOT2wucW6mdXPl[EBwe3Snb3PsZZN1d2enbnXzbZMhcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iVGLBVE1xd3OrdHn2[UBufWy2aT3ueYNt\WG2ZXSgZ4VtdHNiYX\0[ZIhPSCmYYnzMEBKSzVyPUK5Mlgh|ryP Mn7sNlE1PTZ3MkG=
HSC-T6 cells NIDJcGdRem:uaX\ldoF1cW:wIHHzd4F6 NV72W|JLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBz[XRiSGPDMXQ3KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSxiSVO1NF0zQS56IN88US=> NFPXd48zPTN{MkS1OS=>
human A431 cells NVjKVVJEWHKxbHnm[ZJifGmxbjDhd5NigQ>? NULo[252PDhiaB?= M{nWb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczDveoVz\XiycnXzd4lv\yCHcnLCJIlvKHOncoXtMYZz\WVibXXkbZVuKGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBYW1RvMTDhd5NigSxiRVO1NF0{QCEQvF2= MnzPNlQ1PTZyMES=
human MDA-MB-231 cells MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 MnjPNlQhcA>? NUHQdnRvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[Xl? NIrac5AzOjR3OUKwPC=>
human HepG2 cells NWCwR|JUTnWwY4Tpc44h[XO|YYm= NWnmdmVHOjRiaB?= NGTETXFKdmirYnn0bY9vKG:oIH;s[YlkKGGlaXStbY5lfWOnZDD0dolodHmlZYLp[IUhd3[ncj3hZ4N2dXWuYYTpc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiaX7jeYJifGWmIH\vdkAzPCCqcoOgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4w> NUCyRoYyOjF6MkS2PVA>
human HepG2 cells NFXa[3lHfW6ldHnvckBie3OjeR?= M1f0bVI1KGh? MkS3RY51cW:6aXThcpQh[WO2aY\peJkhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKG:uZXnjJIFkcWRvaX7keYNm\CCUT2Og[4Vv\XKjdHnvckBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDETGNHNUSDIHLhd4VlKG[udX;ybY1mfHKrYzDhd5NigSC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= M33sXVIyQDJ2Nkmw
human Caco-2 cells NX36T29PT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX:yOUDPxE1? M2LzdVYh\GG7cx?= MoXHS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gR4Fkdy1{IHPlcIx{KGG2IEK1JJVOKGGodHXyJFYh\GG7cx?= NF65fYIyQDN{NEe2Ny=>
mouse 3T3 cells M3TScWZ2dmO2aX;uJIF{e2G7 M{X0flEuOjBizszN M4i5SlEzKGh? NYPqSVB3SW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IGP3bZN{KGGuYnnuc{Bud3W|ZTCzWFMh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4Uhd2ZiY3XscEBvfW2kZYLzJIF1KDFidH:gNlAhfU1iYX\0[ZIhOTJiaILzJIJ6KGK7IIPjdoF1[2hvd3;1coQh[XO|YYm= Mn3iNlExQDB4NEK=
human MDA-MB-231 cells MnflVJJwdGmoZYLheIlwdiCjc4PhfS=> M3\1d|I1KGh? MlvURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZk> MnnkNlI1PTl{MEi=
human Jurkat cells NXe4XJVJTnWwY4Tpc44h[XO|YYm= NXu4WXhiOTBvNUWg{txO M2TOSFI1KGh? NFnYZ45KdmirYnn0bY9vKG:oIGTOSoFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36gbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGG2IEGwJJRwKDV3IIXNJIFnfGW{IEK0JIhzeyCkeTDlcIVkfHKxcHjvdoV1cWNibX;ibYxqfHlic3jp[pQh[XO|YYm= MoHLNlExQDB4NEK=
human K562 cells M{TtWmZ2dmO2aX;uJIF{e2G7 M4HmeVI1KGh? M3XDWGlv\HWldHnvckBw\iB4NzDrSIEhdGGvaX7pckBz\WOncITvdkBmgHC{ZYPzbY9vKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KG[ub4egZ5l1d22ndIL5JIFv[Wy7c3nz NX;2b45zOjF2M{S2NFM>
human HL60 cells NUH6OoNCTnWwY4Tpc44h[XO|YYm= NG\Kb3IzPCCq M{XKSGlv\HWldHnvckBw\iB4NzDrSIEhdGGvaX7pckBz\WOncITvdkBmgHC{ZYPzbY9vKGmwIHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KG[ub4egZ5l1d22ndIL5JIFv[Wy7c3nz MnzPNlE1OzR4MEO=
human Raji cells NEiwPGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NETPeIQyOCEQvF2= NUTo[ZE4PDhiaB?= NHLHfFdIem:5dHigbY5pcWKrdHnvckBi\2GrboP0JIh2dWGwIGLhbokh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZZQhOTBidV2gZYZ1\XJiNEigbJJ{KGK7IITyfZBidiCkbIXlJIJie2WmIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nzJIlvKHC{ZYPlcoNmKG:oIIP1dIVzd3irZHWg[Il{dXW2YYPl NHzZO4gzOTR|NE[wNy=>
human PC3 cells NHzzTYdRem:uaX\ldoF1cW:wIHHzd4F6 Moi3NVAuOTByIN88US=> NF\4UYY1QCCq NEjl[XJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDheEAyOCC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KGinbX;jfZRwdWW2cnnjJINmdGxiY3;1cpRqdmdibXX0bI9l MVOyN|g3PzF4Nx?=
human A431 cells NGHpZYlHfW6ldHnvckBie3OjeR?= NYTid4FQOTByIN88US=> NWfFeJdCOTJiaB?= MlryVoVlfWO2aX;uJI9nKGOudYP0[ZJqdmdib3[gS2ZRNUeSSTDpckBtcXCrZDDyZYZ1eyCxZjDoeY1idiCDNEOxJINmdGy|IHH0JFExOCC3TTDh[pRmeiBzMjDodpMh[nliY3;u[o9k[WxibXnjdo9{[2:yaXOgZY5idHm|aYO= MYqyOFQ2PjByNB?=
human SKBR3 cells NYnOUY1jTnWwY4Tpc44h[XO|YYm= M1HoRlIxOM7:TR?= NXvndHJNOzBibXnudy=> NFH4XpNFd3ewcnXneYxifGmxbjDv[kBGemKEMjDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gV2tDWjNiY3XscJMhcW5ic3XyeY0h\nKnZTDt[YRqfW1iYYSgNlAxKHWPIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w\my3b4Lld4NmdmOnIIP0ZYlvcW6pLXLhd4VlKGOxbn\vZ4FtKG2rY4Lvd4NweGmlIHHuZYx6e2m| NFKzPYIzPDR3NkCwOC=>
human 293T cells NWDEPYhzTnWwY4Tpc44h[XO|YYm= M1T3ZVUxKM7:TR?= NUn4WG9oOTJiaB?= M{ewXmlvcGmkaYTpc44hd2ZiRGnST|FCKGmwIHj1cYFvKDJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEeOSUGgeJJidnOlcnnweIlwdiCjY4Tpeol1gSCjdDC1NEB2VSCjZoTldkAyOiCqcoOgZpkh\HWjbD3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> MmjFNlIyPTR4NkS=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 Ethanol 83 mg/mL (181.07 mM) warming
DMSO 72 mg/mL warmed (157.07 mM)
Water 23 mg/mL warmed (50.17 mM)

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 458.37
化学式

C22H18O11

CAS No. 989-51-5
保管
in solvent
別名 EGCG

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03624556 Recruiting Down Syndrome|Fragile X Syndrome Parc de Salut Mar|Hospital Infantil Universitario Niño Jesús Madrid Spain|Instituto Hispalense de Pediatría Sevilla Spain|Hospital Universitario Marqués de Valdecilla|Institut Jerome Lejeune January 29 2018 Not Applicable
NCT02891538 Recruiting Colon Cancer The University of Texas Health Science Center at San Antonio January 31 2017 Early Phase 1
NCT02832271 Recruiting Endometriosis Chinese University of Hong Kong December 8 2016 Phase 2
NCT03194620 Completed Healthy University of California Davis|Mars Inc. August 2016 Not Applicable
NCT02577393 Enrolling by invitation Lung Neoplasms|Esophagitis|Prevention & Control|Epigallocatechin Gallate Shandong Cancer Hospital and Institute June 2015 Phase 2
NCT02731495 Completed Traumatic Brain Injury National Nutrition and Food Technology Institute|Tehran University of Medical Sciences March 2015 Phase 2|Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Telomeraseシグナル伝達経路

相関Telomerase製品

Tags: (-)-Epigallocatechin Gallateを買う | (-)-Epigallocatechin Gallate ic50 | (-)-Epigallocatechin Gallate供給者 | (-)-Epigallocatechin Gallateを購入する | (-)-Epigallocatechin Gallate費用 | (-)-Epigallocatechin Gallate生産者 | オーダー(-)-Epigallocatechin Gallate | (-)-Epigallocatechin Gallate化学構造 | (-)-Epigallocatechin Gallate分子量 | (-)-Epigallocatechin Gallate代理店
×

春節(旧正月)休暇に伴う納期遅延のお知らせ
上海工場が春節休業となるため、輸入が必要な製品の納期が通常より2週間ほど遅れます。
1月25日までにご注文いただきました製品は通常通り出荷させていただきます。1月28日-2月8日にご注文いただいた製品は2月19日以降の出荷となります。ご不便をおかけいたしますが、何卒ご理解くださいますようお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID